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Robotic surgery can overcome some limitations of Laparoscopic Total 
Mesorectal Excision (L-TME), improving the quality of the surgery. We aim to 
compare the medium-term oncological outcomes of L-TME vs. Robotic Total 
Mesorectal Excision (R-TME) for rectal cancer. 
METHODS 
A retrospective analysis was performed including patients who underwent L-
TME or R-TME between 2011-2017. Patients presenting with metastatic disease or 
R1 resection were excluded. From a total of 680 patients, 136 cases of R-TME were 
matched based on age, gender, stage and time of follow-up with an equal number of 
patients who underwent L-TME. We compared 3-year disease free survival (DFS) 
and overall survival (OS). 
RESULTS 
Major complications were lower in the robotic group (13.2% vs. 22.8%, 
p=0.04), highlighting the anastomotic leakage rate (7.4% vs. 16.9%, p=0.01). 
The 3-year DFS rate for all stages was 69% for L-TME and 84% for R-TME 
(p=0.02). For disease stage III, 3-year DFS was significantly higher in the R-TME 
group. OS was also significantly superior in the robotic group for every stage, 
reaching 86% in stage III. 
In the multivariate analysis, R-TME was a significant positive prognostic 
factor for distant metastasis (OR 0.2 95%CI 0.1, 0.6, p=0.001) and OS (OR 0.2 
95%CI 0.07, 0.4, p=0.000). Moreover, major complications were also found to have a 
negative impact on OS (OR 8.3 95% CI 3.2, 21.6, p=0.000). 
CONCLUSION 
R-TME for rectal cancer can achieve better oncological outcomes compared to
L-TME, especially in stage III rectal cancers. However, a longer follow-up period is
needed to confirm these findings. 
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INTRODUCTION 
The fundamental principles of Total Mesorectal Excision (TME) surgery 
postulated by Bill Heald[1] were to perform surgery in the anatomical and 
embryological plane. This improved outcomes for rectal cancer patients in particular, 
reducing local recurrence. A few clinical trials across the globe have shown 
comparable outcomes between open and laparoscopic TME.[2,3] The minimally 
invasive approach has several advantages.[2,3] However, the adoption of L-TME 
worldwide remains low and varies between 15-45%. This is linked to a flat learning 
curve in L-TME.  
Robotic surgery can offer some distinct advantages that can overcome some of 
these limitations of L-TME. The evolution of the technique has resulted in more 
advanced instruments for colorectal surgery, which make easier the dissection in a 
narrow pelvis, low rectal tumour and anatomical complexity. Thus, the true benefit of 
these advances will be the quality of the specimen resected which leads to reduced 
local recurrence and improved survival. 
To date, there are only a few reports comparing oncologic outcomes of robotic 
and laparoscopic surgery.[4] None of them have demonstrated a significant difference 
between these 2 approaches, although there is a trend towards better oncological 
outcomes after a R-TME. Therefore, we aimed to compare the medium-term 
oncological results of L-TME vs. R-TME for rectal cancer. 
METHODS 
A retrospective analysis was performed based on a prospectively maintained   
database, including patients who had undergone L-TME or R-TME in a single centre 
over a 7-year period (January 2011- December 2017). A total of 680 patients were 
initially included for further analysis. Inclusion criteria were: Rectal tumor at baseline 
which would be considered to require complete TME and underwent either 
laparoscopic or robotic anterior resection with a stapled colorectal anastomosis. 
Patients presenting with metastatic disease or those whom underwent palliative 
resection were excluded from the study, leaving 639 patients for analysis.  
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Tumours were classified according to the distance between the tumour and the 
anal margin and the anatomical extent of the disease (TNM Classification of 
Malignant Tumours, 7th edition –employed in our centre untill December 2017-).  
Patients were divided into 2 groups, based on the type of surgical intervention: 
L-TME or R-TME. Data recorded included patient demographics (sex, age, BMI,
ASA), preoperative staging, postoperative complications (Dindo-Clavien), 
pathological report and oncological outcomes.  
Primary endpoint was to compare 3-year disease free survival (DFS) and 
overall survival (OS). 3-year DFS was defined as the percentage of patients alive 
without recurrence of disease at 3 years measured from the date of surgery. 3-year OS 
was defined as the time from surgery to death from any cause. Secondary outcomes 
included postoperative complications (30-day) and pathological assessment of the 
quality of the specimen.  
Local recurrence was defined as any clinical/radiological or histologic 
evidence of tumour relapse at the primary site. Distant metastases were diagnosed by 
CT scan. 
The patient allocation to each arm was based on surgeon’s preferred approach 
and access to a robotic theatre. 
Statistical analysis 
Descriptive statistics are presented with mean and standard deviation (SD) or 
median and interquartile range (IQR) for quantitative variables.  
A case-control 1:1 design was applied to minimize baseline differences 
between the laparoscopic and the robotic group. Patients were propensity matched 
into those 2 groups. Confounding variables used to compute the propensity score were  
age, gender, BMI, tumour stage and duration of follow-up (less than 6 months, up to 1 
year, between 1 and 2 years, 2 and 3 years, and more than 3 years). The rest of the 
analysis was performed using the matched patients by surgical approach.  
Comparison of differences between groups was carried out using Chi-Squared 
analysis. Differences between median values of the groups were assessed using 
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Mann-Whitney U test. Odds ratios [OR] were computed for dichotomous and 
continuous risk factors between groups and logistic regression was performed, 
selecting those variables that showed a p<0.25 in the univariate analysis. A time-to-
event analysis was performed using the Kaplan-Meier method and comparisons were 
analyzed by the log-rank test. 
All statistical analyses were conducted using SPSS® version 22 software 
(SPSS, Inc., Chicago, IL) and p-values of <0.05 were considered statistically 
significant. 
RESULTS 
Between January 2011 and December 2017, 680 TME were performed in our 
centre. According to the inclusion criteria, 639 were included for analysis. The 
majority of patients were men (66%), with a median age of 68 (15) years. Median 
follow-up of the 639 patients was 37.4 (45) months. A total of 463 (73.5%) TME 
were performed laparoscopically and 176 (27.5%) robotically. 
Two groups, each of 136 patients (Fig. 1) were matched for age, gender, BMI, 
stage and duration of follow-up. 
The rate of conversion was higher in the L–TME group (3.7% vs. 0%, 
p=0.03), and the LOS was significantly longer (7 vs. 6 days, p=0.001). Perioperative 
complications are shown in Table 1. Major complications were lower in the robotic 
group (13.2% vs. 22.8%, p=0.04), highlighting the anastomotic leakage rate, which 
was 7.4% in the R-TME vs. 16.9% in the L-TME group (p=0.01). 
Pathological outcomes were similar in both groups. The median tumour size in 
both groups was similar (35 mm vs. 30 mm in the L-TME, p=0.373), as well as the 
percentage of Extramural Vascular Invasion (EMVI) positive for small or large vessel 
(23% in the L-TME vs. 19% in the R-TME, p=0.472), and the Circumferential 
Resection Margin (CRM) involvement (3.1% vs. 2.3% in the R-TME, p=0.518). 
Distal resection margin (DRM) was found affected in 1% of the patients in the L-
TME group vs. none of them in the R-TME (Table 1). 
The incidence of local recurrence was similar between groups (2.2% R-TME 
group vs. 2.9% L-TME). However, the development of distant metastasis is 
significantly higher in the L-TME (25.7% vs. 11.8% in the R-TME, p=0.003). 
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The 3-year DFS rate was 69% in the laparoscopic group and 84% in the 
robotic group (p=0.02). The 3-year OS rate was 70% in the L-TME groups and 97% 
in the R-TME group (p=0.000). The differences on DFS and OS according to each 
stage between groups are shown in Table 2. The 3-year DFS for disease stage III was 
significantly higher in the R-TME group (74% vs. 46% in L-TME, p=0.004). OS was 
also significantly superior in the robotic group for every stage, reaching 86% in the 
stage III (Fig. 2). 
In the univariate analysis, common factors that influence both the 3-years DFS 
and 3-years OS are shown in Table 3. In the multivariate analysis we show the 
independent factors influencing local recurrence, distant metastasis and overall 
survival. The only independent factor influencing local recurrence were the major 
complications in the postoperative period (Dindo-Clavien ≥ III) (OR 6.3 95% CI 1.2, 
33.3, p=0.03). Moreover, major complications were also found to have a negative 
impact on the overall survival (OR 8.3 95% CI 3.2, 21.6, p=0.000). The robotic 
approach was a significant positive prognostic factor for the development of distant 
metastasis (OR 0.2 95% CI 0.1, 0.6, p=0.001) and the improvement of the OS (OR 
0.2 95% CI 0.07, 0.4, p=0.000). Also the presence of ExtraMural Vascular Invasion 
(EMVI) for small or large vessels is a prognostic risk factor of distant metastasis (OR 
3 95% CI 1.3, 6.7, p=0.007) and decrease in OS (OR 3.7 95% CI 1.4, 9.6, p=0.007). 
DISCUSSION 
The aim of this study was to investigate the impact of the R-TME on medium-
term oncological outcomes of rectal cancer. This is the first study that has 
demonstrated an improvement in 3-year DFS and OS with the robotic approach, 
reaching 74% and 86%, respectively, for disease stage III (p<0.05). There is a lower 
rate of postoperative complications, which could account for some of the survival 
improvement. 
In the L-TME group, the 3-year DFS may appear lower than expected. However, 
our series included all stages patients and in comparison to COLOR II trial were T4 
and T3b tumours were excluded, similar survival figures were reported (69% vs. 
74.8%).[2] Similar results were obtained when analysing long-term results of the 
ALaCaRT trial[5] but, again, T4 tumours were not included in the study. A recent 
8 
propensity-matched analysis including T4 tumours showed a 2-year DFS of 64.9% for 
stage III patients in the laparoscopic group.[6] 
Oncological outcomes of randomized control trials comparing R-TME vs. L-TME 
have not been published yet. However, previous descriptive studies showed 
equivalence in terms on DFS and OS.[4,7-9] Baek et. al[10] reported similar rates of 
3-year DFS and OS (73.7% and 96.2%, respectively) for patients who underwent
robotic surgery for stages I-III rectal cancer (84% and 93%, respectively, in our 
study). A multicentre study reported comparable short-term oncological outcomes 
with robotic rectal cancer surgery, reaching 97% 3-year OS.[11] Kim et al.[12] 
recently published a propensity score matched analysis showing a trend towards 
improved DFS and OS with a robotic resection. Moreover, they also demonstrated 
that the robotic approach was a significant positive prognostic factor for OS. Our 
study strongly supports these findings. 
The main difference between previously mentioned reports and the present study 
is the surgical procedure. The surgery in this study is performed entirely robotically, 
according to the single-docking technique described before,[13] whilst a hybrid 
technique (robotic-assisted TME) is usually employed in other centres,[4,10] in which 
part of the procedure is performed laparoscopically. The advantages that the robot 
provides for this complex procedure are not reflected in a hybrid procedure. 
Conversion to open surgery did not occur in the R-TME group whereas there were 
5 cases in the L-TME group (3.7%), as previous studies noted.[14,15] In the 
ROLARR trial the rate of conversion to open surgery were lower than expected in 
both arms;[16] however, in a subgroup analysis of high-risk cases it suggests a trend 
of less conversion in the R-TME group.[17] The technological advances of the robotic 
system allow the surgeon to perform a more safely dissection in a narrow pelvis. It 
reduces the need of conversion to open surgery and it may thereby decrease the rate of 
postoperative complications. 
In a review of recent literature, the rate of complications is similar between 
groups[14,18] even in obese patients, but the postoperative recovery is faster.[19]  
However, in the present study the outcomes of postoperative recovery were better in 
the R-TME group than in the L-TME group. These results are in accordance to the 
outcomes published in a recent meta-analysis.[20] Major complications occurred 
more frequently in the L-TME (Dindo-Clavien III-IV 22.8% vs. 13.2% in the R-TME, 
p=0.04). Among these patients, AL occurred in 16.9% in the L-TME compared to 
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7.4% in the R-TME (p=0.01). Previous studies have demonstrated that major 
complications such as AL influence both local recurrence and survival.[21,22] 
Consistent with these results, our study showed that the presence of complications 
Dindo-Clavien ≥ III was an independent prognostic factor for local recurrence (OR 
6.3 95% CI 1.2, 33.3, p=0.03) and decreased overall survival in the multivariate 
analysis (OR 8.3 95% CI 3.2, 21.6, p=0.000). Consequently to the higher rate of 
major postoperative complications, a longer LOS was detected in the L-TME group (7 
vs. 6 days, p=0.01), as published previously.[7,18,23,24] This phenomenon could be 
responsible for the delay in starting adjuvant treatment and result in poor survival.[25] 
The rate of local recurrence at 3 years after surgery is very low after a robotic 
TME (2%), compared to previous robotic data that amount to 3.6%.[9] After 
laparoscopic or open surgery, outcomes reported a percentage near 5% in the COLOR 
II trial,[2] similar to the percentage shown in a database over 20000 patients.[26] The 
percentage of preoperative radiotherapy in our institution is low (20%), and the rate of 
complete response is only 3.8% in the R-TME group. However, it is not an 
independent prognostic factor for local recurrence in the multivariate analysis 
(p>0.05). With the higher use of preoperative radiotherapy we may see an increase in 
complete response but this may potentially increase the risk of postoperative 
complications. 
The quality of the TME specimen remains a concern in L-TME. In the CLASICC 
trial, the patients on the laparoscopic group were found to have a higher rate of CRM 
involvement.[27] The ACOSOG Z6051[28] and the ALaCaRT[29] trials also failed 
trying to demonstrate the non-inferiority of the L-TME. Some of the inherent 
difficulties of laparoscopic surgery such as 2D image, a fulcrum effect, limited access 
to narrow pelvis, and amplification of tremor has been overcome by the increased use 
of robotic technology for TME surgery. Robots offer a 3D view, along with endowrist 
instruments and stability of the operating platform. It may also reduce operator 
fatigue, a potentially influential factor in major surgical procedures. Thus, this control 
allows surgeons to replicate the principles of open TME surgery in a minimal access 
fashion. Other recent studies have demonstrated at least non-inferiority of R-TME 
regarding pathological results.[30] Although the findings of the ROLARR trial[16] 
failed to show better pathological outcomes, the sample size was small. In addition, in 
Table 1 we show a lower rate of CRM involved in the robotic group, which is even 
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better than the results of the ROLARR trial[16] (CRM < 1 mm in 5.1% of cases) and 
lower than data out of Korea.[9] However, in our study the mesorectal grade was 
complete in a similar percentage of patients in both groups (95%), whilst previous 
findings suggested better results in the robotic approach.[14,31] The technological 
advantage of the robotic system leads to superior histopathological outcomes and 
hence an improvement in long-term survival.  
The key question remains if long-term oncological outcomes are better in robotic 
rectal cancer surgery. This remains unanswered with the present evidence. Data from 
trials from Korea has shown no difference in outcomes between laparoscopic and 
robotic surgery.[4] However, rectal cancer surgery is very centralised in Korea, 
resulting in high volume surgeons performing over 300 cases per year and the positive 
patient profile with a low BMI allows successful undertaking of laparoscopic rectal 
cancer surgery. Higher conversion rates in L-TME are seen in the European 
population and the literature supports a reduced conversion rate with the use of 
robotic approach.[16,32] 
This is a retrospective non-randomized study, so there are some inevitable biases. 
As most of the patients who underwent L-TME were operated earlier, it could be a 
bias regarding the learning curve. However, the 3 participating surgeons in this study 
had significant experience in TME surgery at the beginning of this study with over a 
hundred TME procedures performed individually. The good outcomes presented in 
this study can only be achieved by a specialized team of robotic surgery experts at a 
high-volume centre. Thus, the results in our single institutional study may not be 
generalized to all situations. 
Comparison between these two groups may have been influenced by patient and 
tumour-related factors including age, gender, BMI, tumour stage or follow up. In 
order to minimise this, we undertook a comparison between two groups matched for 
these confounders. The propensity score matching is a useful method for reducing 
biases between groups. The propensity-matching methodology did not include 
neoadjuvant chemoradiotherapy and MRI risk factors (EMVI, tumour deposits), 
which may have led to heterogeneity or biases; however, the two groups were similar 
on these accounts. 
11 
CONCLUSIONS 
R-TME for rectal cancer can achieve better oncological outcomes compared to
L-TME, especially in stage III rectal cancers. The robotic approach has demonstrated
to be a significant positive prognostic factor for local recurrence and overall survival, 
due to the better postoperative outcomes. 
However, a longer follow-up period is needed to confirm the oncologic 
findings and to support the general adoption of the robotic system for rectal cancer 
surgery. 
COMPLIANCE WITH ETHICAL STANDARDS 
- No funding.
- Authors have no conflict of interest.
- All procedures performed in studies involving humans were in accordance
with ethical standards of the institutional research committee and the 1964
Helsinki declaration and its later amendments.
- Informed consent was obtained from all participants.
12 
REFERENCES 
1. Heald RJ. The 'Holy Plane' of rectal surgery (1988) Journal of the Royal Society
of Medicine 81(9):503-508.
2. Bonjer HJ, Deijen CL, Abis GA, et al (2015) A randomized trial of laparoscopic
versus open surgery for rectal cancer. The New England journal of medicine
372(14):1324-1332.
3. Jeong SY, Park JW, Nam BH, et al (2014) Open versus laparoscopic surgery for
mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN
trial): survival outcomes of an open-label, non-inferiority, randomised controlled
trial. The Lancet. Oncology 15(7):767-774.
4. Park EJ, Cho MS, Baek SJ, et al (2015) Long-term oncologic outcomes of robotic
low anterior resection for rectal cancer: a comparative study with laparoscopic
surgery. Annals of surgery 261(1):129-137.
5. Stevenson ARL, Solomon MJ, Brown CSB, et al (2018) Disease-free Survival
and Local Recurrence After Laparoscopic-assisted Resection or Open Resection
for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum
Randomized Clinical Trial. Annals of surgery 269(4):596-602
6. Manchon-Walsh P, Aliste L, Biondo S, et al (2016) A propensity-score-matched
analysis of laparoscopic vs open surgery for rectal cancer in a population-based
study. Colorectal disease 21(4):441-450
7. Baek SJ, Al-Asari S, Jeong DH, et al (2013) Robotic versus laparoscopic
coloanal anastomosis with or without intersphincteric resection for rectal cancer.
Surgical endoscopy 27(11):4157-4163.
8. Cho MS, Baek SJ, Hur H, et al (2015) Short and long-term outcomes of robotic
versus laparoscopic total mesorectal excision for rectal cancer: a case-matched
retrospective study. Medicine 94(11):e522.
9. Baik SH, Kim NK, Lim DR, Hur H, Min BS, Lee KY (2013) Oncologic
outcomes and perioperative clinicopathologic results after robot-assisted tumor-
specific mesorectal excision for rectal cancer. Annals of surgical oncology
20(8):2625-2632.
10. Baek JH, McKenzie S, Garcia-Aguilar J, Pigazzi A (2010) Oncologic outcomes
of robotic-assisted total mesorectal excision for the treatment of rectal cancer.
Annals of surgery 251(5):882-886.
13 
11. Pigazzi A, Luca F, Patriti A, et al (2010) Multicentric study on robotic tumor-
specific mesorectal excision for the treatment of rectal cancer. Annals of surgical
oncology 17(6):1614-1620.
12. Kim J, Baek SJ, Kang DW, et al (2017) Robotic Resection is a Good Prognostic
Factor in Rectal Cancer Compared with Laparoscopic Resection: Long-term
Survival Analysis Using Propensity Score Matching. Diseases of the colon and
rectum 60(3):266-273.
13. Ahmed J, Siddiqi N, Khan L, Kuzu A, Parvaiz A (2016) Standardized technique
for single-docking robotic rectal surgery. Colorectal disease 18(10):O380-o384.
14. Baik SH, Kwon HY, Kim JS, et al (2009) Robotic versus laparoscopic low
anterior resection of rectal cancer: short-term outcome of a prospective
comparative study. Annals of surgical oncology 16(6):1480-1487.
15. Polat F, Willems LH, Dogan K, Rosman C (2019) The oncological and surgical
safety of robot-assisted surgery in colorectal cancer: outcomes of a longitudinal
prospective cohort study.
16. Jayne D, Pigazzi A, Marshall H, et al (2017) Effect of Robotic-Assisted vs
Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy
Among Patients Undergoing Resection for Rectal Cancer: The ROLARR
Randomized Clinical Trial. Jama  318(16):1569-1580.
17. Wright JD. Robotic-Assisted Surgery: Balancing Evidence and Implementation
(2017) Jama. 318(16):1545-1547.
18. Kang J, Yoon KJ, Min BS, et al (2013) The impact of robotic surgery for mid and
low rectal cancer: a case-matched analysis of a 3-arm comparison--open,
laparoscopic, and robotic surgery. Annals of surgery 257(1):95-101.
19. Gorgun E, Ozben V, Costedio M, Stocchi L, Kalady M, Remzi F. (2016) Robotic
versus conventional laparoscopic rectal cancer surgery in obese patients.
Colorectal disease 18(11):1063-1071.
20. Sun XY, Xu L, Lu JY, Zhang GN (2019) Robotic versus conventional
laparoscopic surgery for rectal cancer: systematic review and meta-analysis.
Minimally invasive therapy & allied technologies : MITAT : official journal of
the Society for Minimally Invasive Therapy 1-8.
21. Bell SW, Walker KG, Rickard MJ, et al (2003) Anastomotic leakage after
curative anterior resection results in a higher prevalence of local recurrence. The
British journal of surgery  90(10):1261-1266.
14 
22. Odermatt M, Miskovic D, Flashman K, et al (2015) Major postoperative
complications following elective resection for colorectal cancer decrease long-
term survival but not the time to recurrence. Colorectal disease 17(2):141-149.
23. Cheng CL, Rezac C (2018) The role of robotics in colorectal surgery. BMJ
(Clinical research ed.). 360:j5304.
24. Asklid D, Gerjy R, Hjern F, et al (2019) Robotic vs laparoscopic rectal tumour
surgery: a cohort study. Colorectal disease 21(2):191-199
25. Arhi CS, Burns EM, Bouras G, Aylin P, Ziprin P, Darzi A (2018) Complications
after discharge and delays in adjuvant chemotherapy following colonic resection:
a cohort study of linked primary and secondary care data. Colorectal disease
21(3):307-314
26. Herold ALP, Matzel, K, O'Connell, PR. (2017) Coloproctology. Springer Berlin
Heidelberg.
27. Guillou PJ, Quirke P, Thorpe H, et al (2005) Short-term endpoints of
conventional versus laparoscopic-assisted surgery in patients with colorectal
cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet
(London, England). 365(9472):1718-1726.
28. Fleshman J, Branda M, Sargent DJ, et al (2015) Effect of Laparoscopic-Assisted
Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic
Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. Jama.
314(13):1346-1355.
29. Stevenson AR, Solomon MJ, Lumley JW, et al (2015) Effect of Laparoscopic-
Assisted Resection vs Open Resection on Pathological Outcomes in Rectal
Cancer: The ALaCaRT Randomized Clinical Trial. Jama. 314(13):1356-1363.
30. Aselmann H, Kersebaum JN, Bernsmeier A, et al (2018) Robotic-assisted total
mesorectal excision (TME) for rectal cancer results in a significantly higher
quality of TME specimen compared to the laparoscopic approach-report of a
single-center experience. International journal of colorectal disease 33(11):1575-
1581.
31. Milone M, Manigrasso M, Velotti N, et al (2019) Completeness of total
mesorectum excision of laparoscopic versus robotic surgery: a review with a
meta-analysis. International journal of colorectal disease. 34(6):983-991.
15 
32. Ahmed J, Cao H, Panteleimonitis S, Khan J, Parvaiz A (2017) Robotic vs
laparoscopic rectal surgery in high-risk patients. Colorectal disease 19(12):1092-
1099.
16 
FIGURE LEGENDS AND FIGURES 
Figure 1. Flowchart of patient selection. 
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Figure 2. Comparison of 3-year DFS and OS between patients treated with L-TME 
and R-TME for rectal cancer. A) All stages, B) Stage I; C) Stage II; D) Stage III.   
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Table 1. Patients’ characteristics and postoperative pathological outcomes after 
propensity score matching. 
L-TME
n = 136 
R-TME
n = 136 
p value 
Age (median –IQR-) (year) 69 (14) 68 (16) p=0.545 
Sex (Male:Female) (%) 76:24 76:24 p=1 
BMI 27 (6) 27 (5) p=0.635 
ASA 
p=0.096 I-II 74% 83% 
   III 26% 17% 
MRI 
Tumour distance from ARJ 
(median –IQR-) (cm) 
6 (9) 6 (6) 
p=0.160 
CRM + 16.2% 21.1% p=0.362 
EMVI + 40.7% 38.8% p=0.812 
Neoadjuvant chemoradiotherapy 16.2% 20.6% p=0.348 
TRG (%) 
p=0.267 
   1 16.6% 3.8% 
   2 44.5% 50% 
   3 27.8% 23.1% 
   4 0 15.4% 
   5 11.1% 7.7% 
Conversion to open 3.7% 0 p=0.03 
Dindo-Clavien 
p=0.04 I-II 77.2% 86.8% 
III-V 22.8% 13.2% 
Anastomotic leak (AL) 
   Radiological leak 












   Stage II 17% 13% 
   Stage III 65% 61% 
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Follow-up (median months – IQR-) 28 (61) 25 (34) p=0.067 
Histopathology 
TNM stage (%) 
p=1 
   0 0.7% 0.7% 
   I 31.6% 31.6% 
   II 30.1% 30.1% 
   III 37.5% 37.5% 
T (%) 
p=0.067 
   0 0.7% 0.7% 
   1 12.5% 11% 
   2 24.4% 36% 
   3 52.9% 48.5% 
   4 9.5% 3.8% 
N (%) 
p=0.658    1 23.5% 26.4% 
   2 14% 11% 
Grade of differentiation 
p=0.752 
   Well 3.8% 4.5% 
   Moderate 88.6% 90.3% 
   Poor 4.8% 2.2% 
   Mucinous 2.9% 3% 
Tumour size (median – IQR-) (mm) 30 (15) 35 (20.5) p=0.373 
EMVI + (%) 23.1% 19.3% p=0.472 
Lymph nodes harvested (median – IQR-) (%) 17 (10) 18 (10) p=0.940 
DRM < 2 mm (%) 1% 0 p=0.424 
CRM + (%) 3.1% 2.3% p=0.518 
TME (%) 
p=0.635 
   Complete 96% 96.2% 
   Nearly complete 4% 3% 
   Incomplete 0 0.8% 
*ASA = American Society of Anesthesiologists; BMI = Body Mass Index; CRM =
Circumferential Rectal Margin; DRM = Distal Resection Margin; EMVI=ExtraMural 
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Vascular Invasion; LOS = Length Hospital Stay; NS = Non significant; TME = Total 
Mesorectal Excision; TRG = Tumour Regression Grade. 
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Table 2. 3-year Disease Free Survival (DFS) and overall survival (OS). Comparison 
between patients with laparoscopic and robotic TME. 
L-TME
n = 136 
R-TME
n = 136 
p value 
Local recurrence 2.9% 2.2% p=0.469 
Distant metastasis 25.7% 11.8% p=0.003 
3-y DFS
   All stages 69% 84% p=0.000 
   Stage I 88% 93% p=0.722 
   Stage II 76% 85% p=0.571 
   Stage III 46% 74% p=0.01 
3-y OS
   All stages 70% 93% p=0.000 
   Stage I 81% 98% p=0.07 
   Stage II 62% 98% p=0.002 
   Stage III 64% 86% p=0.04 
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Table 3. Univariate and multivariate analysis of factors influencing Disease Free 
Survival and overall survival. 
Local Recurrence Distal Metastasis Overall Survival 
Univariate Multivariate 
(95% CI) 
p Univariate Multivariate 
(95% CI) 
p Univariate Multivariate 
(95% CI)
p 
R-TME 0.7 0.003 0.2 (0.1-0.6) 0.001 0.000 0.2 (0.07-
0.4) 
0.000 
Age (≥75) 0.09 2.4 (0.3-7.3) 0.9 0.5 0.000 4.3 (1.7-
10.8) 
0.002 
Sex (Male) 0.5 0.4 0.2 0.8 (0.2-2.8) 0.8 
BMI (≥30) 0.1 1.5 (0.2-8.9) 0.6 0.8 0.8 
ASA (≥III) 0.6 0.3 0.003 1.8 (0.7-4.8) 0.2 
Low rectum 
   (<5cm ARJ) 
0.4 0.4 0.6 
Preop radio 0.6 0.3 0.5 
Preop chemo 0.6 0.4 0.4 
Dindo ≥ III 0.1 6.3 (1.2-33.3) 0.03 0.25 1.3 (0.5-3.7) 0.6 0.000 8.3 (3.2-
21.6) 
0.000 
LOS ≥ 8 days 0.5 0.01 1.8 (0.9-3.8) 0.1 0.005 0.8 (0.3-2.4) 0.7 
Tumour size 
      (≥ 3 cm) 
0.1 3.2 (0.3-31.3) 0.3 0.6 0.07 1.3 (0.5-3.5) 0.6 
TNM stage III 0.2 2.6 (0.4-14.9) 0.3 0.000 4.1 (1.9-8.9) 0.000 0.06 1.8 (0.7-4.7) 0.2 
CRM < 1 mm 0.8 0.04 1.4 (0.2-
13.9) 
0.7 0.04 3.8 (0.4-
42.2) 
0.3 
DRM < 2 mm 0.8 0.8 0.8 
EMVI + 0.6 0.000 3 (1.3-6.7) 0.007 0.006 3.7 (1.4-9.6) 0.007 
TME Incompl 0.8 0.8 0.8 
Differentiation 
    (grades 3-4) 
0.6 0.1 1.9 (0.5-7.3) 0.3 0.4 
Chemotherapy 0.6 0.007 0.9 (0.3-2.3) 0.8 0.6 
ARJ=Anorectal Junction; ASA=American Society of Anesthesiologists; BMI=body 
mass index, CI=confidence interval, CRM=circumferential resection margin; DRM = 
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Distal Resection Margin; EMVI=ExtraMural Vascular Invasion; TME=Total 
Mesorectal Excision; L-TME=Laparoscopic TME; R-TME=Robotic TME. 
Figure 1. Flowchart of patient selection.
Figure 2. Comparison of 3-year DFS and OS between patients
treated with L-TME and R-TME for rectal cancer. A) All stages, B)
Figure 2. Comparison of 3-year DFS and OS between patients
treated with L-TME and R-TME for rectal cancer. C) Stage II; D)
Table 1. Patients’ characteristics and postoperative pathological outcomes after 
propensity score matching. 
L-TME
n = 136 
R-TME
n = 136 
p value 
Age (median –IQR-) (year) 69 (14) 68 (16) p=0.545 
Sex (Male:Female) (%) 76:24 76:24 p=1 
BMI 27 (6) 27 (5) p=0.635 
ASA 
p=0.096 I-II 74% 83% 
   III 26% 17% 
MRI 
Tumour distance from ARJ 
(median –IQR-) (cm) 
6 (9) 6 (6) 
p=0.160 
CRM + 16.2% 21.1% p=0.362 
EMVI + 40.7% 38.8% p=0.812 
Neoadjuvant chemoradiotherapy 16.2% 20.6% p=0.348 
TRG (%) 
p=0.267 
   1 16.6% 3.8% 
   2 44.5% 50% 
   3 27.8% 23.1% 
   4 0 15.4% 
   5 11.1% 7.7% 
Conversion to open 3.7% 0 p=0.03 
Dindo-Clavien 
p=0.04 I-II 77.2% 86.8% 
III-V 22.8% 13.2% 
Anastomotic leak (AL) 
   Radiological leak 












   Stage II 17% 13% 
   Stage III 65% 61% 
Table 1. Patients’ characteristics and postoperative pathological
outcomes after propensity score matching.
Follow-up (median months – IQR-) 28 (61) 25 (34) p=0.067 
Histopathology 
TNM stage (%) 
p=1 
   0 0.7% 0.7% 
   I 31.6% 31.6% 
   II 30.1% 30.1% 
   III 37.5% 37.5% 
T (%) 
p=0.067 
   0 0.7% 0.7% 
   1 12.5% 11% 
   2 24.4% 36% 
   3 52.9% 48.5% 
   4 9.5% 3.8% 
N (%) 
p=0.658    1 23.5% 26.4% 
   2 14% 11% 
Grade of differentiation 
p=0.752 
   Well 3.8% 4.5% 
   Moderate 88.6% 90.3% 
   Poor 4.8% 2.2% 
   Mucinous 2.9% 3% 
Tumour size (median – IQR-) (mm) 30 (15) 35 (20.5) p=0.373 
EMVI + (%) 23.1% 19.3% p=0.472 
Lymph nodes harvested (median – IQR-) (%) 17 (10) 18 (10) p=0.940 
DRM < 2 mm (%) 1% 0 p=0.424 
CRM + (%) 3.1% 2.3% p=0.518 
TME (%) 
p=0.635 
   Complete 96% 96.2% 
   Nearly complete 4% 3% 
   Incomplete 0 0.8% 
*ASA = American Society of Anesthesiologists; BMI = Body Mass Index; CRM =
Circumferential Rectal Margin; DRM = Distal Resection Margin; EMVI=ExtraMural 
Vascular Invasion; LOS = Length Hospital Stay; NS = Non significant; TME = Total 
Mesorectal Excision; TRG = Tumour Regression Grade. 
Table 2. 3-year Disease Free Survival (DFS) and overall survival (OS). Comparison 
between patients with laparoscopic and robotic TME. 
L-TME
n = 136 
R-TME
n = 136 
p value 
Local recurrence 2.9% 2.2% p=0.469 
Distant metastasis 25.7% 11.8% p=0.003 
3-y DFS
   All stages 69% 84% p=0.000 
   Stage I 88% 93% p=0.722 
   Stage II 76% 85% p=0.571 
   Stage III 46% 74% p=0.01 
3-y OS
   All stages 70% 93% p=0.000 
   Stage I 81% 98% p=0.07 
   Stage II 62% 98% p=0.002 
   Stage III 64% 86% p=0.04 
Table 2. 3-year Disease Free Survival (DFS) and overall survival
(OS). Comparison between patients with laparoscopic and
Table 3. Univariate and multivariate analysis of factors influencing Disease Free Survival and overall survival. 
 
 Local Recurrence Distal Metastasis Overall Survival  
Univariate Multivariate 
(95% CI) 
p Univariate Multivariate 
(95% CI) 
p Univariate Multivariate 
(95% CI) 
p 
R-TME 0.7   0.003 0.2 (0.1-0.6) 0.001 0.000 0.2 (0.07-
0.4) 
0.000 
Age (≥75) 0.09 2.4 (0.3-7.3) 0.9 0.5   0.000 4.3 (1.7-
10.8) 
0.002 
Sex (Male) 0.5   0.4   0.2 0.8 (0.2-2.8) 0.8 
BMI (≥30) 0.1 1.5 (0.2-8.9) 0.6 0.8   0.8   
ASA (≥III) 0.6   0.3   0.003 1.8 (0.7-4.8) 0.2 
Low rectum 
   (<5cm ARJ) 
0.4   0.4   0.6   
Preop radio 0.6   0.3   0.5   
Preop chemo 0.6   0.4   0.4   
Dindo ≥ III 0.1 6.3 (1.2-33.3) 0.03 0.25 1.3 (0.5-3.7) 0.6 0.000 8.3 (3.2-
21.6) 
0.000 
LOS ≥ 8 days 0.5   0.01 1.8 (0.9-3.8) 0.1 0.005 0.8 (0.3-2.4) 0.7 
Tumour size 
      (≥ 3 cm) 
0.1 3.2 (0.3-31.3) 0.3 0.6   0.07 1.3 (0.5-3.5) 0.6 
Table 3. Univariate and multivariate analysis of factors influencing Disease Free Survival and
overall survival.
TNM stage III 0.2 2.6 (0.4-14.9) 0.3 0.000 4.1 (1.9-8.9) 0.000 0.06 1.8 (0.7-4.7) 0.2 
CRM < 1 mm 0.8   0.04 1.4 (0.2-
13.9) 
0.7 0.04 3.8 (0.4-
42.2) 
0.3 
DRM < 2 mm 0.8   0.8   0.8   
EMVI + 0.6   0.000 3 (1.3-6.7) 0.007 0.006 3.7 (1.4-9.6) 0.007 
TME Incompl 0.8   0.8   0.8   
Differentiation 
    (grades 3-4) 
0.6   0.1 1.9 (0.5-7.3) 0.3 0.4   
Chemotherapy 0.6   0.007 0.9 (0.3-2.3) 0.8 0.6   
 
ARJ=Anorectal Junction; ASA=American Society of Anesthesiologists; BMI=body mass index, CI=confidence interval, CRM=circumferential 
resection margin; DRM = Distal Resection Margin; EMVI=ExtraMural Vascular Invasion; TME=Total Mesorectal Excision; L-
TME=Laparoscopic TME; R-TME=Robotic TME. 
 
